公司資料
Cytokinetics 股價、新聞與催化劑
- 股票代碼:
- CYTK
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
75.87 USD (+2.35%)
收盤價
最後更新: 2026年8月17日
9.63B USD
市值
股價為何變動
The latest monitored company update is “Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).” The corresponding closing-price reaction is not yet available.
公司概覽
Muscle Biology Specialization
Cytokinetics develops and commercializes medicines that modulate muscle function. Its portfolio is centered on cardiac muscle biology and diseases in which altered contractility contributes directly to symptoms and clinical outcomes.
MYQORZO in Obstructive HCM
MYQORZO, or aficamten, is a cardiac myosin inhibitor approved in the United States and European Union for adults with symptomatic obstructive hypertrophic cardiomyopathy. The product launched in the United States in January 2026 and forms the company’s emerging commercial franchise.
Aficamten Lifecycle Development
Cytokinetics is seeking to broaden aficamten across hypertrophic cardiomyopathy. The Phase 3 ACACIA-HCM trial met its dual primary endpoints in symptomatic non-obstructive HCM, while MAPLE-HCM supports a supplemental application in obstructive disease and additional studies address Japanese patients.
Heart-Failure Pipeline
Omecamtiv mecarbil is a cardiac myosin activator in the confirmatory Phase 3 COMET-HF trial for symptomatic heart failure with severely reduced ejection fraction. This program extends the company’s muscle-directed approach beyond HCM.
未來催化劑
- Initial European launch of MYQORZO in Germany expected in the second quarter of 2026.
- FDA action on the aficamten supplemental NDA supported by MAPLE-HCM expected by November 14, 2026.
- Full results from the Phase 3 ACACIA-HCM trial to be presented at a medical congress.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。